Ozempic works by mimicking a natural gut hormone called GLP-1 that your body releases after eating. The active ingredient, semaglutide, activates GLP-1 receptors throughout your body to lower blood sugar, slow digestion, and reduce appetite. It’s FDA-approved for managing type 2 diabetes and reducing cardiovascular risk in people with type 2 diabetes and heart disease, though it’s widely prescribed off-label for weight loss.
How It Lowers Blood Sugar
When you eat, your gut naturally produces GLP-1, a hormone that tells your pancreas to release insulin. Ozempic amplifies this signal. It binds to GLP-1 receptors on insulin-producing cells in the pancreas, triggering a chain of events inside those cells: an enzyme called adenylate cyclase ramps up, which ultimately causes the cells to push out more insulin into the bloodstream. The key detail is that this process is glucose-dependent, meaning it only kicks in when blood sugar is actually elevated. That’s why Ozempic carries a lower risk of dangerously low blood sugar compared to some older diabetes medications.
At the same time, Ozempic suppresses glucagon, a hormone that tells your liver to dump stored sugar into the bloodstream. By dialing down glucagon while dialing up insulin, it attacks high blood sugar from both directions. In clinical trials, the 1 mg weekly dose reduced A1c (a measure of average blood sugar over three months) by 1.5% to 1.8% after 30 to 56 weeks of treatment.
How It Reduces Appetite
Ozempic doesn’t just work in the pancreas. It reaches specific areas of the brain that lack the usual blood-brain barrier, particularly a region called the area postrema in the brainstem. This area expresses GLP-1 receptors and accumulates semaglutide after injection. Once activated, these neurons relay signals to other brain regions involved in energy balance, including areas that regulate satiety, stress hormones, and the motivation to eat.
Research published in Cell Metabolism mapped this pathway in detail: semaglutide activates neurons in the area postrema, which then engage a network of downstream neurons that project to regions controlling hunger and fullness. This is why people on Ozempic consistently report feeling less hungry and thinking about food less often. It’s not just willpower or a placebo effect. The drug is physically altering the signaling in circuits that drive appetite.
How It Slows Digestion
Ozempic also activates GLP-1 receptors on nerve cells in the stomach, which slows the rate at which food moves from the stomach into the small intestine. This delayed gastric emptying means nutrients enter the bloodstream more gradually, preventing sharp blood sugar spikes after meals. It also contributes to feeling full longer after eating.
The slowdown is most dramatic after the first dose and tends to diminish somewhat with continued use as the body partially adapts. That said, evidence suggests gastric emptying can remain impaired for up to eight weeks after stopping the drug. This is why patients are typically advised to stop Ozempic at least three weeks before any planned surgery involving anesthesia, since a full stomach during sedation raises the risk of aspiration.
Cardiovascular Benefits
Beyond blood sugar and weight, Ozempic reduces the risk of serious cardiovascular events in people with type 2 diabetes. A pooled analysis of two major trials (SUSTAIN 6 and PIONEER 6) found a 24% reduction in the combined risk of heart attack, stroke, and cardiovascular death among semaglutide users compared to placebo. Ozempic is now FDA-approved specifically for reducing cardiovascular risk in adults with type 2 diabetes and heart disease, and for improving kidney and cardiovascular health in adults with type 2 diabetes and chronic kidney disease.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation, each occurring in 5% or more of patients in clinical trials. At the 2 mg dose, about 34% of patients experienced GI side effects compared to roughly 31% at the 1 mg dose. Most of these symptoms are worst during the early weeks and during dose increases, then tend to improve. Still, about 3% to 4% of patients on the 0.5 mg or 1 mg doses discontinued treatment because of GI problems, compared to less than 1% on placebo.
Ozempic also carries an FDA boxed warning (the most serious type) about thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors. It’s unknown whether this risk applies to humans, but the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to watch for include a lump in the neck, difficulty swallowing, or persistent hoarseness.
How It’s Taken
Ozempic is a once-weekly injection given under the skin of the abdomen, thigh, or upper arm. Treatment starts at 0.25 mg per week for the first four weeks, which is a non-therapeutic dose designed only to let your body adjust and minimize nausea. After that, the dose increases to 0.5 mg, then potentially to 1 mg or 2 mg depending on how well your blood sugar responds and how you tolerate the drug. Each step up typically lasts at least four weeks before the next increase. The maximum recommended dose is 2 mg once weekly.
Ozempic vs. Wegovy
Ozempic and Wegovy contain the exact same active ingredient, semaglutide, but they’re approved for different purposes. Ozempic is approved for type 2 diabetes management and related cardiovascular and kidney protection. Wegovy is approved for weight management in adults and children 12 and older, for a type of liver disease called MASH, and for cardiovascular risk reduction in adults with obesity or overweight and existing heart disease. Wegovy’s maximum dose is slightly higher at 2.4 mg compared to Ozempic’s 2 mg. When doctors prescribe Ozempic “off-label” for weight loss, they’re using the diabetes-approved version for a purpose it wasn’t specifically approved for, though the drug works through the same mechanisms regardless of which label it carries.